2022
Whole-Genome Sequencing Has the Potential To Improve Treatment for Rifampicin-Resistant Tuberculosis in High-Burden Settings: a Retrospective Cohort Study
Cox H, Goig GA, Salaam-Dreyer Z, Dippenaar A, Reuter A, Mohr-Holland E, Daniels J, Cudahy PGT, Nicol MP, Borrell S, Reinhard M, Doetsch A, Beisel C, Gagneux S, Warren RM, Furin J. Whole-Genome Sequencing Has the Potential To Improve Treatment for Rifampicin-Resistant Tuberculosis in High-Burden Settings: a Retrospective Cohort Study. Journal Of Clinical Microbiology 2022, 60: e02362-21. PMID: 35170980, PMCID: PMC8925891, DOI: 10.1128/jcm.02362-21.Peer-Reviewed Original ResearchMeSH KeywordsAntitubercular AgentsCohort StudiesHumansMicrobial Sensitivity TestsMycobacterium tuberculosisRetrospective StudiesRifampinSouth AfricaTuberculosis, Multidrug-ResistantConceptsDrug susceptibility testingRifampicin-resistant tuberculosisShort regimenMDR/RR-TB patientsMDR/RR-TBRR-TB patientsRetrospective cohort studyMore effective treatment regimensHigh-burden settingsRoutine drug susceptibility testingTB drug resistanceEffective treatment regimensWhole-genome sequencingTolerable regimensCohort studyRetrospective cohortRR-TBRegimen changeTreatment regimensTreatment recommendationsPatient outcomesTreatment individualizationClinical dataIndividualized treatmentIneffective drugsPhylogeography and transmission of M. tuberculosis in Moldova: A prospective genomic analysis
Yang C, Sobkowiak B, Naidu V, Codreanu A, Ciobanu N, Gunasekera KS, Chitwood MH, Alexandru S, Bivol S, Russi M, Havumaki J, Cudahy P, Fosburgh H, Allender CJ, Centner H, Engelthaler DM, Menzies NA, Warren JL, Crudu V, Colijn C, Cohen T. Phylogeography and transmission of M. tuberculosis in Moldova: A prospective genomic analysis. PLOS Medicine 2022, 19: e1003933. PMID: 35192619, PMCID: PMC8903246, DOI: 10.1371/journal.pmed.1003933.Peer-Reviewed Original ResearchMeSH KeywordsAntitubercular AgentsDrug Resistance, Multiple, BacterialGenotypeHumansMoldovaMycobacterium tuberculosisPhylogenyPhylogeographyProspective StudiesTuberculosisTuberculosis, Multidrug-ResistantConceptsMultidrug-resistant tuberculosisDrug-resistant M. tuberculosisM. tuberculosis strainsPutative transmission clustersM. tuberculosisTransmission clustersMultidrug-resistant M. tuberculosis strainsTuberculosis strainsMultiple M. tuberculosis strainsCulture-positive TB casesLocal transmissionMDR-TB epidemicDrug-susceptible tuberculosisDrug resistance mutationsDrug resistance profilesUrgency of interventionTB casesDemographic dataNew casesTuberculosisInadequate treatmentNatural historyResistance mutationsBeijing lineageMycobacterium tuberculosis
2021
Potential contribution of HIV during first-line tuberculosis treatment to subsequent rifampicin-monoresistant tuberculosis and acquired tuberculosis drug resistance in South Africa: a retrospective molecular epidemiology study
Cox H, Salaam-Dreyer Z, Goig GA, Nicol MP, Menardo F, Dippenaar A, Mohr-Holland E, Daniels J, Cudahy PGT, Borrell S, Reinhard M, Doetsch A, Beisel C, Reuter A, Furin J, Gagneux S, Warren RM. Potential contribution of HIV during first-line tuberculosis treatment to subsequent rifampicin-monoresistant tuberculosis and acquired tuberculosis drug resistance in South Africa: a retrospective molecular epidemiology study. The Lancet Microbe 2021, 2: e584-e593. PMID: 34766068, PMCID: PMC8563432, DOI: 10.1016/s2666-5247(21)00144-0.Peer-Reviewed Original ResearchMeSH KeywordsDrug ResistanceFemaleHIV InfectionsHumansMolecular EpidemiologyMycobacterium tuberculosisRetrospective StudiesRifampinSouth AfricaTuberculosisTuberculosis, Multidrug-ResistantConceptsFirst-line tuberculosis treatmentPrevious tuberculosis treatmentRifampicin-resistant tuberculosisRifampicin-monoresistant tuberculosisTuberculosis treatmentHIV positivityCohort studyLarge-scale prospective cohort studyResistance acquisitionPrevious treatmentRetrospective cohort studyProspective cohort studyTuberculosis drug resistancePatient-level dataLogistic regression analysisWhole-genome sequencingMolecular epidemiology studiesProspective databaseMDR tuberculosisRetrospective cohortFemale sexHigh burdenPatientsHIVEpidemiology studiesRifampicin-Monoresistant Tuberculosis Is Not the Same as Multidrug-Resistant Tuberculosis: a Descriptive Study from Khayelitsha, South Africa
Salaam-Dreyer Z, Streicher EM, Sirgel FA, Menardo F, Borrell S, Reinhard M, Doetsch A, Cudahy PGT, Mohr-Holland E, Daniels J, Dippenaar A, Nicol MP, Gagneux S, Warren RM, Cox H. Rifampicin-Monoresistant Tuberculosis Is Not the Same as Multidrug-Resistant Tuberculosis: a Descriptive Study from Khayelitsha, South Africa. Antimicrobial Agents And Chemotherapy 2021, 65: 10.1128/aac.00364-21. PMID: 34460307, PMCID: PMC8522772, DOI: 10.1128/aac.00364-21.Peer-Reviewed Original ResearchMeSH KeywordsAntitubercular AgentsHIV InfectionsHumansIsoniazidMicrobial Sensitivity TestsMutationMycobacterium tuberculosisRifampinSouth AfricaTuberculosisTuberculosis, Multidrug-ResistantConceptsMultidrug-resistant TBRMR-TBRR-TBPatient-level clinical dataPhenotypic drug susceptibility testingRifampicin-monoresistant tuberculosisRR-TB patientsMultidrug-resistant tuberculosisHIV-positive individualsRifampin-resistant tuberculosisDrug susceptibility testingRifampin monoresistanceHIV infectionMDR isolatesTB drugsRisk factorsClinical dataSusceptibility testingSubset of isolatesTuberculosisDescriptive studyMycobacterium tuberculosisAvailable WGS dataSignificant differencesPatients
2018
Spatially targeted screening to reduce tuberculosis transmission in high-incidence settings
Cudahy PGT, Andrews JR, Bilinski A, Dowdy DW, Mathema B, Menzies NA, Salomon JA, Shrestha S, Cohen T. Spatially targeted screening to reduce tuberculosis transmission in high-incidence settings. The Lancet Infectious Diseases 2018, 19: e89-e95. PMID: 30554997, PMCID: PMC6401264, DOI: 10.1016/s1473-3099(18)30443-2.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsCommunicable Disease ControlHIVHumansIncidenceMass ScreeningMycobacterium tuberculosisPrevalenceTuberculosis, Multidrug-ResistantWhole Genome SequencingConceptsTuberculosis incidenceLow tuberculosis incidence settingsActive case-finding strategyHigh tuberculosis (TB) incidence countriesCase-finding strategyTuberculosis control strategiesHigh-incidence settingsInfectious causesIncidence settingsIncidence countriesTuberculosis transmissionTreatment outcomesActive screeningOnward transmissionSystematic reviewInfectious individualsInfectious periodTuberculosisIncidenceDeathCauseProximal causeHIVMixed resultsMortalityTrends in C-Reactive Protein, D-Dimer, and Fibrinogen during Therapy for HIV-Associated Multidrug-Resistant Tuberculosis.
Cudahy PGT, Warren JL, Cohen T, Wilson D. Trends in C-Reactive Protein, D-Dimer, and Fibrinogen during Therapy for HIV-Associated Multidrug-Resistant Tuberculosis. American Journal Of Tropical Medicine And Hygiene 2018, 99: 1336-1341. PMID: 30226135, PMCID: PMC6221241, DOI: 10.4269/ajtmh.18-0322.Peer-Reviewed Original ResearchConceptsC-reactive proteinMulti-drug resistant tuberculosisD-dimerMedian C-reactive proteinSerum C-reactive proteinHigher baseline fibrinogenMDR-TB therapyHIV-positive adultsDrug-resistant tuberculosisHIV-positive participantsHigher CRP concentrationsEarly treatment modificationBaseline fibrinogenTreatment initiationResistant tuberculosisCRP concentrationsTreatment modificationTreatment outcomesTreatment responseHigh riskHigh mortalityNormal levelsOlder ageEarly responseFibrinogen
2017
Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: a systematic review and meta-analysis
Nathavitharana RR, Cudahy PG, Schumacher SG, Steingart KR, Pai M, Denkinger CM. Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: a systematic review and meta-analysis. European Respiratory Journal 2017, 49: 1601075. PMID: 28100546, PMCID: PMC5898952, DOI: 10.1183/13993003.01075-2016.Peer-Reviewed Original ResearchConceptsLine probe assayComposite reference standardINH resistanceRIF resistanceSystematic reviewMultidrug-resistant tuberculosis (MDR-TB) casesRapid drug susceptibility testingMultidrug-resistant tuberculosisProbe assayTuberculosis detectionDrug susceptibility testingSmear-positive specimensSmear-negative specimensReference standardM. tuberculosis detectionMycobacterium tuberculosis detectionPulmonary TBTuberculosis casesNew line probe assayStudy qualityIsoniazid resistanceQUADAS-2Indirect testingRifampicinUnique studies